Abstract
IntroductionVH-IVUS is increasingly used in clinical trials to classify vulnerable thin-capped fibroatheroma (TCFA). However, VH-IVUS has not been validated for classifying coronary plaque against the gold standard of human post-mortem...
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
